Hans O Kalkman

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone
    Natarajan Subramanian
    Novartis Pharma AG, Research Nervous System, Basel, Switzerland
    Prog Neuropsychopharmacol Biol Psychiatry 26:553-60. 2002
  2. ncbi Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders
    H O Kalkman
    Novartis Pharma, Basel, Switzerland
    Neuropsychopharmacology 25:904-14. 2001
  3. ncbi Antischizophrenic activity independent of dopamine D2 blockade
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building WSJ 360 405, CH 4002 Basel, Switzerland
    Expert Opin Ther Targets 6:571-82. 2002
  4. ncbi alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building WSJ 360 405, CH 4002 Basel, Switzerland
    Eur J Pharmacol 462:33-40. 2003
  5. ncbi GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis
    H O Kalkman
    Novartis Pharma AG, Preclinical Research, Nervous System Department, Basel, Switzerland
    J Neural Transm 110:803-12. 2003
  6. ncbi Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building S 360 405 CH 4002 Basel, Switzerland
    Life Sci 73:1151-9. 2003
  7. ncbi The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia
    Hans O Kalkman
    Neuroscience Research, Novartis Institutes of Biomedical Research Basel, Building WSJ 360 4 05, Novartis Pharma AG, CH4002 Basel, Switzerland
    Pharmacol Ther 110:117-34. 2006
  8. ncbi Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia
    Hans O Kalkman
    Novartis Pharma AG, Novartis Institutes of Biomedical Research Basel, WSJ 386 11 40, Postfach, CH 4002 Basel, Switzerland
    Pharmacol Ther 121:115-22. 2009
  9. ncbi Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia
    Hans O Kalkman
    Novartis Pharma AG, Novartis Institutes of Biomedical Research Basel, WSJ 386 11 40, Postfach, CH 4002 Basel, Switzerland
    Prog Neuropsychopharmacol Biol Psychiatry 35:410-4. 2011

Collaborators

Detail Information

Publications9

  1. ncbi Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone
    Natarajan Subramanian
    Novartis Pharma AG, Research Nervous System, Basel, Switzerland
    Prog Neuropsychopharmacol Biol Psychiatry 26:553-60. 2002
    ..However, the comparable receptor binding profile of P88-8991 indicates that it is likely to contribute to the clinical profile of iloperidone...
  2. ncbi Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders
    H O Kalkman
    Novartis Pharma, Basel, Switzerland
    Neuropsychopharmacology 25:904-14. 2001
    ....
  3. ncbi Antischizophrenic activity independent of dopamine D2 blockade
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building WSJ 360 405, CH 4002 Basel, Switzerland
    Expert Opin Ther Targets 6:571-82. 2002
    ..In this review, the possible pharmacological approaches and their respective advantages and disadvantages are discussed...
  4. ncbi alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building WSJ 360 405, CH 4002 Basel, Switzerland
    Eur J Pharmacol 462:33-40. 2003
    ..Clozapine had the highest alpha(2C)/D(2) selectivity, and iloperidone the highest alpha(2C)/alpha(2A) ratio. It is hypothesised that alpha(2C)-adrenoceptor blockade contributes to improvement of cognitive function...
  5. ncbi GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis
    H O Kalkman
    Novartis Pharma AG, Preclinical Research, Nervous System Department, Basel, Switzerland
    J Neural Transm 110:803-12. 2003
    ..GAD(67) levels would thus be a surrogate marker for psychosis liability. Pharmacological principles that raise GAD(67) expression levels could represent novel targets for antipsychotic therapy...
  6. ncbi Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building S 360 405 CH 4002 Basel, Switzerland
    Life Sci 73:1151-9. 2003
    ..59 +/- 0.20; n = 6), followed by alpha(2C) (pK(B) 7.83 +/- 0.06; n = 15), 5-HT(1A) (pK(B) 7.69 +/- 0.18; n = 10), D(2A) (pK(B) 7.53 +/- 0.04; n = 11) and 5-HT(6) (pK(B) 7.11 +/- 0.08; n = 11) receptors...
  7. ncbi The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia
    Hans O Kalkman
    Neuroscience Research, Novartis Institutes of Biomedical Research Basel, Building WSJ 360 4 05, Novartis Pharma AG, CH4002 Basel, Switzerland
    Pharmacol Ther 110:117-34. 2006
    ..However, a major challenge that remains to be solved is how the PI3K-PKB pathway can be activated without increasing the risk of cancer...
  8. ncbi Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia
    Hans O Kalkman
    Novartis Pharma AG, Novartis Institutes of Biomedical Research Basel, WSJ 386 11 40, Postfach, CH 4002 Basel, Switzerland
    Pharmacol Ther 121:115-22. 2009
    ....
  9. ncbi Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia
    Hans O Kalkman
    Novartis Pharma AG, Novartis Institutes of Biomedical Research Basel, WSJ 386 11 40, Postfach, CH 4002 Basel, Switzerland
    Prog Neuropsychopharmacol Biol Psychiatry 35:410-4. 2011
    ....